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OBJECTIVES On the basis of quantitative coronary angiography data, the cholesteryl ester transfer protein
(CETP) TaqIB gene polymorphism has been postulated to predict the progression of
coronary atherosclerosis and response to cholesterol-lowering therapy.
BACKGROUND Cholesteryl ester transfer protein mediates the exchange of lipids between anti-atherogenic
high-density lipoprotein (HDL) and atherogenic apolipoprotein B containing lipoproteins
and therefore plays a key role in human lipid metabolism. Hence, CETP gene polymorphisms
may alter susceptibility to atherosclerosis.
METHODS To investigate the significance of the CETP TaqIB gene polymorphism with respect to
clinical end points, we used the Cholesterol And Recurrent Events (CARE) cohort. The
CARE study was designed to investigate the effect of five years of pravastatin therapy on
coronary events.
RESULTS We found that the odds ratios for the primary end point were not significantly different from
unity for the three genetic subgroups after five years of placebo treatment. Furthermore,
pravastatin induced similar changes in total cholesterol, low-density lipoprotein cholesterol,
and HDL cholesterol among TaqIB genotypes, and both nonfatal myocardial infarction and
deaths from coronary heart disease were reduced to the same extent in all three genotypes.
CONCLUSIONS In the CARE cohort, the CETP TaqIB polymorphism does not predict cardiovascular events or
discriminate between those who will or will not benefit from pravastatin treatment. (J Am Coll
Cardiol 2004;43:854–7) © 2004 by the American College of Cardiology Foundationa
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iecause coronary heart disease (CHD) is an important
ause of death, the timely identification of high-risk patients
s essential for the prevention of mortality and morbidity. In
he REGRESS study, we have shown that a cholesteryl
ster transfer protein (CETP) gene polymorphism (denoted
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therosclerosis as assessed by computer-assisted quantitative
ngiography (1). In addition, a pharmacogenetic interaction
etween the TaqIB genotype and response to cholesterol-
owering therapy (pravastatin) was identified. Using angio-
raphic outcome as a surrogate end point for cardiovascular
vents, it was hypothesized that this genetic marker could
iscriminate between those who will and those who will not
enefit from pravastatin therapy with respect to cardiovas-
ular end points. To test this hypothesis, we have studied
he CETP TaqIB polymorphism and a CETP promoter
olymorphism (C629A) in the Cholesterol And Recur-
ent Events (CARE) cohort, a large prospective placebo-
ontrolled secondary prevention trial with clinical end
oints as outcome (2). The 629 polymorphism was
ncluded in this analysis because it is in strong linkage
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March 3, 2004:854–7 CETP TaqIB Polymorphism in the CARE Studyisequilibrium with the TaqIB polymorphism and has been
hown to directly affect CETP promoter activity.
Cholesteryl ester transfer protein mediates the exchange
f lipids between anti-atherogenic high-density lipoprotein
HDL) and atherogenic apolipoprotein B containing li-
oproteins, and therefore plays a key role in human lipid
etabolism. Hence, CETP gene polymorphisms may alter
usceptibility to atherosclerosis. In line with this concept,
ETP gene variation has been shown to be associated with
lasma CETP, HDL cholesterol (HDL-c) levels (3–5), and
isk for CHD (3,4). Most studies indicate that the TaqIB
1B1 genotype is associated with higher plasma CETP and
ower HDL-c levels than the B2B2 genotype.
We present TaqIB data on 2,764 men and 441 women of
he CARE study, which was designed to investigate the effect
f five years of pravastatin therapy on coronary events after a
revious myocardial infarction (MI). The primary end point of
he trial was death from CHD or nonfatal MI. For the present
nalysis, men and women were investigated separately.
ETHODS
tudy design and patients. The design of the CARE trial
as been described elsewhere (2). In short, patients were
ecruited from 80 participating centers—13 in Canada and
7 in the U.S. Men and postmenopausal women were
ligible if they had an acute MI between three and 20
onths before randomization, were 21 to 75 years of age,
nd had plasma total cholesterol levels of 240 mg/dl (6.2
mol/l), low-density lipoprotein cholesterol (LDL-c) levels
f 115 to 174 mg/dl (3 to 4.5 mmol/l), fasting triglyceride
evels of350 mg/dl (4 mmol/l), fasting glucose levels of no
ore than 220 mg/dl (12 mmol/l), left ventricular ejection
ractions of no less than 25%, and no symptomatic conges-
ive heart failure. Diabetes and hypertension were either
iagnosed by a physician or defined by patients’ use of
nti-diabetic or antihypertensive medication. This was ver-
fied in a sample of the medical records. Physical exercise
as estimated on the basis of filled-out questionnaires. The
rimary end point of the trial was death from CHD
including fatal MI, either definite or probable; sudden
eath; death during a coronary intervention; and death from
ther coronary causes) or symptomatic (unless during non-
ardiac surgery) nonfatal MI confirmed by serum creatine
inase measurements. The protocol was approved by the
afety and data monitoring committees and the institutional
Abbreviations and Acronyms
CARE  Cholesterol And Recurrent Events study
CETP  cholesteryl ester transfer protein
CHD  coronary heart disease
HDL-c high-density lipoprotein cholesterol
LDL-c  low-density lipoprotein cholesterol
MI  myocardial infarctioneview boards of all participating centers. Baboratory analyses. Plasma total cholesterol, HDL-c,
nd triglyceride levels were measured by the core laboratory,
nd LDL-c levels were calculated (2).
Genomic DNA was prepared from 1 ml of frozen blood
ith Purigene extraction kit (Gentra Systems, Minneapolis,
innesota). All the genotyping was done with enzyme
inked immunosorbent assay–based single base extension
ssay using SNPStreamTM 25K genotyping system (Or-
hid Bioscience, Princeton, New Jersey) (6). The sequences
f the oligonucleotide primers used in these assays were as
ollows:
TaqIB PCR-forward primer:
CCAGGTATAGGGATTTGTGTTTG
TaqIB PCR-reverse primer:
CAAATATACACCAACCTCCTAATCTTTAC
TaqIB base extension primer:
GTCTGCGACCXAGAATCACTGGGGTTC
629 PCR-forward primer:
CAGTTTCTCCCGGAGGCA
629 PCR-reverse primer:
GTCCTCTATGTAGACTTTCCTTGATATGC
629 base extension primer:
TTGATATGCATAAAATAACTCTGGG
tatistical analyses. A total of 3,274 of the 4,159 subjects
n the CARE study had sufficient DNA for genotyping.
mong the 3,274 subjects, 69 were excluded from the
nalysis because of failed genotyping. The total number of
ubjects used in the analyses was 3,205 (441 women and
,764 men). Among these, 1,604 subjects (218 women and
,386 men) were in the pravastatin treatment group, and
,601 subjects (223 females and 1,378 males) were in the
lacebo group. All the statistical analyses were done sepa-
ately for women and men.
The associations of TaqIB genotypic variation with
uantitative lifestyle parameters, baseline plasma lipid levels,
nd changes of these lipid levels during the study were
nalyzed using analysis of variance and F tests. The TaqIB
enotype associations with categorical lifestyle parameters
ere analyzed using contingency tables and chi-square tests.
ogistic regression with likelihood ratio and Score tests
ere used with baseline HDL-c as a covariate to assess the
nteraction between TaqIB genotypic variation and the
reatment effect on the clinical end points. The ratio of odds
f the clinical event for subjects treated with pravastatin
elative to that for subjects treated with placebo were
alculated for each genotype. Logistic regression was also
sed with baseline HDL-c as a covariate to analyze the
nfluence of TaqIB genotypic variation on clinical events in
he placebo group alone. In these analyses, the ratios of the
dds of the clinical event for subjects with the B1B1 or
1B2 genotype, each relative to those for subjects with the
2B2 genotype, were determined. All these analyses were
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CETP TaqIB Polymorphism in the CARE Study March 3, 2004:854–7lso performed for the 629 variant. The analyses were
arried out with SAS version 8.1 (7).
ESULTS
here were no significant differences in lifestyle parameters
r CHD risk factors among these genotypes at baseline
xcept for a lower percentage of smokers in female B1B2
arriers than in B1B1 and B2B2 genotypes (Table 1).
Table 2 gives lipid and lipoprotein concentration in the
hree genetic subgroups. A significant and apparently dose-
ependent relationship between the number of copies of the
1 allele and lower HDL-c at baseline was observed (p 
.001 in men and p  0.002 in women), whereas no relation-
hip with other lipids or lipoproteins was present.
The odds ratios for the primary end point were not signif-
cantly different from unity for the three genetic subgroups
fter five years of placebo treatment. Furthermore, pravastatin
nduced similar changes in total cholesterol, LDL-c, and
DL-c among TaqIB genotypes. We found that nonfatal MI
nd deaths from CHD were reduced to the same extent in all
hree genotypes (Fig. 1). Similar results were obtained with
able 1. Baseline Characteristics According to CETP TaqIB Ge
Characteristic
Men
B1B1
n  907
B1B2
n  1,390
B2B
n 
eneral Mean (SD) Mean (SD) Mean
Age (yrs) 57.8 (9.7) 58.2 (9.09) 58.1 (
Race: white (%) 93.1 94.3 93.
Body mass index (kg/m2) 27.7 (4.1) 27.5 (4.2) 27.6 (
Waist hip ratio 0.95 (0.1) 0.95 (0.1) 0.95 (
Systolic BP (mm Hg) 128.8 (18.0) 127.7 (17.8) 128.9 (
Diastolic BP (mm Hg) 79.0 (10.0) 78.6 (10.2) 78.8 (
isk factors
Smoker (%) 19.6 20.8 19.
Exercise (%) 74.4 69.6 74.
Hypertension (%) 41.7 39.1 41.
Diabetes mellitus (%) 11.6 13.7 11.
Family history of CAD (%) 39.5 38.8 39.
1 denotes the presence of a restriction site for TaqIB in intron 1 of the CETP gen
CETP  cholesteryl ester transfer protein; SD  Lower 95% confidence level, U
able 2. Baseline Plasma Lipids and Lipoproteins and CHD Eve
Men
B1B1
(n  907)
B1B2
(n  1,390)
B2B2
(n  46
otal cholesterol
(mmol/l)
5.35 (0.46) 5.35 (0.45) 5.40 (0.4
DL cholesterol
(mmol/l)
0.95 (0.20) 0.98 (0.22) 1.03 (0.2
DL cholesterol
(mmol/l)
3.60 (0.39) 3.57 (0.38) 3.55 (0.3
oge (triglycerides) 1.33 (0.38) 1.31 (0.39) 1.34 (0.3
(n  449) (n  695) (n  23
HD events (OR*) 0.78 (0.47, 1.29) 1.12 (0.71, 1.76) 1.0
Odds ratio of CETP TaqIB genotypes (B1B1 and B1B2 each relative to B2B2) fo
B1  the presence of a restriction site for TaqIB in intron 1 of the CETP gene,
eart disease death or nonfatal myocardial infarction; HDL  high-density lipoprote
5% confidence level).ther end points, including coronary revascularization, unstable
ngina, and stroke. This was also true when the 629
olymorphism was used to define genotypes.
ISCUSSION
n accordance with our results from the REGRESS and
umerous other studies (3–5), we observed a significant and
pparently dose-dependent relationship between the number
f copies of the B1 allele and lower HDL-c at baseline in the
ARE cohort, whereas no relationship with other lipids or
ipoproteins was present. We could also confirm that pravasta-
in induced similar changes in total cholesterol, LDL-c, and
DL-c among TaqIB genotypes. Unexpectedly, however, the
dds ratios for the primary end points (i.e., death from CHD
r nonfatal MI) were not significantly different from unity for
he three genetic subgroups after five years of placebo treat-
ent. Accordingly, in the pravastatin treated group, nonfatal
I and deaths from CHD were reduced to the same extent in
ll three genetic subgroups.
These findings are in agreement with those found for a
ohort of healthy U.S. physicians (5), but they contrast with
e
p Value
Women
p Value
B1B1
n  177
B1B2
n  203
B2B2
n  67
Mean (SD) Mean (SD) Mean (SD)
0.65 62.0 (8.9) 61.3 (8.4) 59.3 (10.2) 0.11
0.41 90.1 93.1 90.1 0.49
0.75 27.4 (5.5) 27.4 (5.5) 27.5 (5.9) 0.99
0.57 0.9 (0.1) 0.9 (0.1) 0.8 (0.1) 0.86
0.25 136.0 (19.7) 132.8 (19.1) 132.4 (20.6) 0.22
0.67 77.7 (10.3) 77.8 (9.9) 76.9 (10.3) 0.82
0.69 39.8 30.1 39.8 0.03
0.08 65.1 58.9 65.1 0.61
0.24 56.1 50.7 56.1 0.49
0.28 17.0 20.2 17.0 0.55
0.84 44.1 41.9 44.1 0.08
B2 its absence.
95% confidence level; BP  blood pressure.
ccording to the CETP TaqIB Genotype
p
Value
Women
p
Value
B1B1
(n  171)
B1B2
(n  203)
B2B2
(n  67)
0.10 5.54 (0.40) 5.55 (0.39) 5.66 (0.36) 0.09
 0.0001 1.12 (0.27) 1.15 (0.27) 1.26 (0.32) 0.002
0.09 3.61 (0.37) 3.61 (0.35) 3.62 (0.34) 0.97
0.52 1.31 (0.38) 1.29 (0.4) 1.27 (0.4) 0.77
(n  89) (n  97) (n  37)
0.17* 0.72 (0.22, 2.31) 1.36 (0.46, 4) 1.0 0.34
ovascular end points in the placebo group.
2 its absence. CETP  cholesteryl ester transfer protein; CHD events  coronary
L  low-density lipoprotein; OR  odds ratio (lower 95% confidence level; uppernotyp
2
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March 3, 2004:854–7 CETP TaqIB Polymorphism in the CARE Studyata from the Framingham Offspring Study (FOS) (4) and the
eterans Affairs HDL-c Intervention Trial (VA-HIT) (3), in
hich significant associations between TaqIB and cardiovas-
ular end points were observed. However, upon adjustment for
ither: 1) age, body mass index, systolic blood pressure,
iabetes, smoking, alcohol consumption, beta-blocker use, and
otal and HDL-c (FOS); or 2) age, diabetes, smoking, and
ypertension (VA-HIT), this association was reduced in mag-
itude, losing statistical significance. In conclusion, the asso-
iation between CETP genotype and CHD is as yet unclear.
evertheless, with respect to our previous analysis, we are
onfronted with a disconnection between surrogate end points
n the REGRESS study and cardiovascular end points in the
ARE study. Maybe angiographic end points are not equiv-
lent to clinical events in every respect, perhaps for CETP in
articular. In this respect, we would like to address that
ngiography can assess the atherosclerotic process only locally,
hereas an atherothrombotic event is ultimately defined by
dditional factors, including plaque stability, coagulation, and
brinolysis.
Thus, in the CARE cohort, the CETP TaqIB and
C629A polymorphisms do not predict cardiovascular
vents, nor do they discriminate between those who will or
igure 1. Gender-TaqIB genotype-specific odds ratios for death from
ardiovascular disease or nonfatal myocardial infarction in the pravastatin
elative to placebo group after five years of treatment. The bars represent
he upper limit of the 95% confidence interval of the odds ratio.ill not benefit from pravastatin treatment. Finally, unpub-
ished REGRESS data on TaqIB and risk question the
oncept that a single genetic marker can predict the clinical
utcome of a complex, chronic disease such as atheroscle-
osis. Instead, the effects of variation at multiple gene loci
hould be studied simultaneously in order to unravel the
ighly complex genetic component of atherogenesis and
ardiovascular disease.
cknowledgments
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